Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases
Twenty chronic viral hepatitis patients, mainly with hepatitis B related with progression to liver cirrhosis were included for an assay of serum collagen markers: PICP (carboxy terminal propeptide of type I procollagen), PIIINP (amino terminal propeptide of type III procollagen), and 7S-IV (7S-domain type IV collagen). PICP is increased in 20% of chronic hepatitis patients with a mean of 190.3 ng/ml, which is not different from that of the follow-up concentration in liver cirrhosis, where 35% of cases were abnormal with a mean of 220.5 ng/ml. The serum level and percent of abnormality of PIIICP in chronic hepatitis and in liver cirrhosis are 23.5 ng/ml vs 14.8 ng/ml and 90% vs 100%, respectively (P>0.05). PICP/PIIINP is significantly higher during liver cirrhosis (15.11 vs 10.08,P<0.05). PICP during chronic hepatitis is not related to serum biochemical changes, while PICP during liver cirrhosis and PIIINP are correlated with hepatic enzymes. 7S-IV in chronic hepatitis and in liver cirrhosis is 14.0 ng/ml vs 10.9 ng/ml, respectively; both were positively correlated with hepatic enzymes. These results suggest that PICP/PIIINP is a better indicator of hepatic fibrogenesis than either PICP or PIIINP alone in viral hepatitis. A ratio of more than 12 is suggestive of liver cirrhosis.
Key wordshepatic fibrosis PICP PIIINP 7S-IV collagen viral hepatitis
Unable to display preview. Download preview PDF.
- 2.Okuda K: Imaging methods.In Liver Cirrhosis. JL Boyer, L Bianchi (eds). Lancaster, MTP Press, 1987, pp 213–275Google Scholar
- 3.Lee CM, Liaw YF, Huang MJ, Chen TJ, Chu CM, Sheen IS, Lin HH: Serum level ofN-terminal peptide of procollagen type III in chronic liver disease. J Formosan Med Assoc 86:769–773, 1987Google Scholar
- 4.Colombo M, Annoni G, Donato MF, Martines D, Zaramella MG, Bianchi PA, Piperno A, Tiribelli C: Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology 5:475–479, 1985PubMedGoogle Scholar
- 10.Shahin M, Schuppan D, Waldherr R, Risteli J, Risteli L. Savolainen ER, Oesterling C, Rahman HMA, Sahly ME, Razek SMA, Ruby OE, Koch A, Seitz HK: Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 15:637–644, 1992PubMedGoogle Scholar
- 15.Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay for the carboxyterminal propeptide of human type I procollagen (PICP). Clin Chem 367:1328–1332, 1990Google Scholar
- 21.Igarashi S, Funaki N, Hatahara T, Inoue T: Clinical significance of the assay of 7S and type IV collagen in the sera with various liver disease—comparison with PIIIP and laminin P1 concentrations. Acta Hepatol Jpn 31:524–530, 1990 (in Japanese)Google Scholar
- 27.Preedy VR, Moniz C, Hammond B, Baldwin D, Petero TJ: Changes in bone collagen content after chronic ethanol feeding. Bone 11:222, 1990. (abstract)Google Scholar